Tvardi Therapeutics (NASDAQ:TVRD) Issues Quarterly Earnings Results

Tvardi Therapeutics (NASDAQ:TVRD) announced its earnings results on Friday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04), FiscalAI reports.

Tvardi Therapeutics Trading Up 7.3%

Shares of NASDAQ:TVRD opened at $1.90 on Friday. Tvardi Therapeutics has a 1 year low of $1.50 and a 1 year high of $43.65. The business has a fifty day simple moving average of $2.49 and a 200 day simple moving average of $3.19. The firm has a market cap of $17.82 million, a price-to-earnings ratio of -0.68 and a beta of 0.39.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. American Financial Group Inc. purchased a new stake in shares of Tvardi Therapeutics during the 4th quarter worth about $962,000. Vestal Point Capital LP bought a new stake in shares of Tvardi Therapeutics in the 3rd quarter valued at approximately $6,508,000. Geode Capital Management LLC bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $2,617,000. BlackRock Inc. bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $181,000. Finally, Invesco Ltd. acquired a new position in Tvardi Therapeutics in the third quarter worth approximately $3,219,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on TVRD shares. Wall Street Zen downgraded Tvardi Therapeutics to a “strong sell” rating in a report on Saturday, July 18th. HC Wainwright began coverage on Tvardi Therapeutics in a research note on Monday, June 8th. They issued a “buy” rating and a $9.00 price objective for the company. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research report on Wednesday, July 8th. BTIG Research lowered their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Tvardi Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.